In fact, the analysis of ESR1 mutations through liquid biopsy, by measuring circulating tumor DNA (ctDNA), has gained clinical relevance as a non-invasive approach to molecularly monitor patients with metastatic breast cancer (mBC) [6,[9], [10], [11]]. Here, ESR1 is linked to neoplasm.